The GPR35 expression pattern is associated with overall survival in male patients with colorectal cancer
© 2022. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences..
BACKGROUND: G protein-coupled receptor 35 (GPR35) is involved in the carcinogenesis; however, limited data exist on its relevance for overall survival (OS) and disease-specific survival (DSS) in patients with cancer.
METHODS: We have examined The Cancer Genome Atlas dataset to check the relations between GPR35 expression pattern and OS or DSS of patients with colorectal cancer (CRC).
RESULTS: The performed analysis showed a negative association between positive GPR35 expression Z score and OS in males, which remains statistically significant in advanced stages of colon (COAD) and rectal (READ) adenocarcinoma combined.
CONCLUSIONS: These findings suggest the prognostic value of early testing of GPR35 in male patients with an increased risk of CRC development and warrant further clinical confirmation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Pharmacological reports : PR - 74(2022), 4 vom: 27. Aug., Seite 709-717 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mackiewicz, Tomasz [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 05.08.2022 Date Revised 08.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s43440-022-00371-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341445436 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341445436 | ||
| 003 | DE-627 | ||
| 005 | 20231226011810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s43440-022-00371-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1138.xml |
| 035 | |a (DE-627)NLM341445436 | ||
| 035 | |a (NLM)35622222 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mackiewicz, Tomasz |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The GPR35 expression pattern is associated with overall survival in male patients with colorectal cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.08.2022 | ||
| 500 | |a Date Revised 08.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences. | ||
| 520 | |a BACKGROUND: G protein-coupled receptor 35 (GPR35) is involved in the carcinogenesis; however, limited data exist on its relevance for overall survival (OS) and disease-specific survival (DSS) in patients with cancer | ||
| 520 | |a METHODS: We have examined The Cancer Genome Atlas dataset to check the relations between GPR35 expression pattern and OS or DSS of patients with colorectal cancer (CRC) | ||
| 520 | |a RESULTS: The performed analysis showed a negative association between positive GPR35 expression Z score and OS in males, which remains statistically significant in advanced stages of colon (COAD) and rectal (READ) adenocarcinoma combined | ||
| 520 | |a CONCLUSIONS: These findings suggest the prognostic value of early testing of GPR35 in male patients with an increased risk of CRC development and warrant further clinical confirmation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a Disease-specific survival | |
| 650 | 4 | |a G protein-coupled receptor 35 | |
| 650 | 4 | |a GPR35 | |
| 650 | 4 | |a Overall survival | |
| 650 | 7 | |a GPR35 protein, human |2 NLM | |
| 650 | 7 | |a Receptors, G-Protein-Coupled |2 NLM | |
| 700 | 1 | |a Jacenik, Damian |e verfasserin |4 aut | |
| 700 | 1 | |a Talar, Marcin |e verfasserin |4 aut | |
| 700 | 1 | |a Fichna, Jakub |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological reports : PR |d 2005 |g 74(2022), 4 vom: 27. Aug., Seite 709-717 |w (DE-627)NLM154978965 |x 2299-5684 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2022 |g number:4 |g day:27 |g month:08 |g pages:709-717 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s43440-022-00371-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2022 |e 4 |b 27 |c 08 |h 709-717 | ||